Global kidney cancer drugs market is expected to grow at an estimated CAGR of 17% over the forecast period. Renal cell carcinoma (RCC) is the most common form of cancer found in the kidney. It is a very common urologic tumors in adults which account for around 3% of all human hostilities. The reason for the disease is yet unknown. However, the clinical removal of the cells found to be cancerous from the kidney offers a total treatment of the disease. Additionally, large drugs variety are also available for the treatment of kidney cancer when identified at an earlier stage. The occurrence rate of RCC is projected to increase with time with the growth in obesity, increase in the number of smokers and reduction in physical activities. Renal cancer symptoms are similar to other disorders which make it difficult to detect which, in turn, in the detection of disease in its last stage which makes difficult for the patient to survive. Mostly, RCC is diagnosed by chance during the routine checkups of the patient for other conditions.
The global kidney cancer drugs market is majorly driven by the changing lifestyles of people. The predominance of lifestyle influenced diseases which includes too much drinking and smoking along with few chronic diseases which include kidney tumors and cancer are the key factors fueling the growth of kidney cancer drugs market globally. Along with these factors, the geriatric population, aged 45 and above, are highly prone to chronic diseases including kidney cancer thereby increasing the occurrences of kidney cancer.
Patients and clinicians favorably prefer Kidney cancer drugs over the targeted remedies. These kidney cancer drugs are life protracting treatment procedures that are available for those patients who are suffering from advanced stage of the metastatic tumor. Furthermore, the occurrence of kidney cancer is expected to be higher in developed countries than the developing countries. Also, a limited number of approved drugs for the treatment of kidney cancer is available on the market. Thus, these factors altogether have assisted the market in converting it into a billion dollar market.
However, the branded drugs for the cure of kidney cancer have been priced highly. These high prices of the drugs are projected to hinder the overall market growth. As a result, a majority of the consumers prefer generic kidney cancer drug variants over branded drugs. This will also obstruct the global kidney cancer drugs market.
The global kidney cancer drugs market is classified by primary branded drugs. These branded drugs include Inlyta (Axitinib), Afinitor (Everolimus), Votrient (Pazopanib), Sutent (Sunitinib), Nexavar (Sorafenib), Avastin (Bevacizumab), Torisel (Temsirolimus), and Proleukin (Interlukin-2/Aldesleukin). The stent was the largest product type having the highest market share. However, Votrient is anticipated to witness the highest growth rate over the next eight years.
The global kidney cancer drugs market is also segmented by the pipeline analysis of the potential drugs. These type of drugs are at present in its trial phase of 2 and 3. Few of these drugs projected to be commercialized and launched over the next eight years include Keytruda, AGS-003, Opdivo, Cabozantinib, and Dovitinib.
North American kidney cancer drugs market accounted for the majority of the overall market in the past few years. The region benefitted mainly due to the rising occurrences of kidney cancer and other types of kidney diseases. Additionally, the U.S. has the largest market of pharmaceuticals which accounted for over 90% of the market of North America.
The Asia-Pacific market is estimated to witness the fastest growth rate for the kidney cancer drugs market over the forecast period. Lower cost of drugs production, increasing patients base and growing awareness among the patients who suffer from diseases such as renal cell carcinoma are projected to drive the regional growth of kidney cancer drugs market.
The global kidney cancer drugs market displays high competition among the industry participants as the present market is highly consolidated. Few of the established pharmaceutical giants include Pfizer Inc., Bayer Pharma AG, GlaxoSmithKline Plc, Hoffman-La Roche and Novartis AG. The major industry participants are capitalizing heavily in research & development and generating many strategies including collaborations, new product launches, expansions and innovations to uphold their market share in the global kidney cancer drugs market.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.